BR0006823A - Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial - Google Patents

Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial

Info

Publication number
BR0006823A
BR0006823A BR0006823-3A BR0006823A BR0006823A BR 0006823 A BR0006823 A BR 0006823A BR 0006823 A BR0006823 A BR 0006823A BR 0006823 A BR0006823 A BR 0006823A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
polypeptide compound
cyclic polypeptide
injection preparation
commercial package
Prior art date
Application number
BR0006823-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Seiji Sawai
Akihiro Kasai
Kazumi Otomo
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16210881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0006823(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of BR0006823A publication Critical patent/BR0006823A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0006823-3A 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial BR0006823A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP18771399 1999-07-01
PCT/JP2000/004381 WO2001002002A1 (en) 1999-07-01 2000-06-29 Stabilized pharmaceutical composition in lyophilized form

Publications (1)

Publication Number Publication Date
BR0006823A true BR0006823A (pt) 2001-06-05

Family

ID=16210881

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0006823-3A BR0006823A (pt) 1999-07-01 2000-06-29 Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0006823A BRPI0006823B8 (pt) 1999-07-01 2000-06-29 composição farmacêutica estabilizada, preparação de injeção, e kit comercial

Country Status (28)

Country Link
US (2) US6774104B1 (https=)
EP (1) EP1107777B1 (https=)
JP (2) JP3381722B2 (https=)
KR (1) KR100454784B1 (https=)
CN (2) CN1179748C (https=)
AR (1) AR024634A1 (https=)
AT (1) ATE280583T1 (https=)
AU (1) AU752265B2 (https=)
BR (2) BR0006823A (https=)
CA (1) CA2341568C (https=)
CZ (1) CZ295720B6 (https=)
DE (1) DE60015279T2 (https=)
ES (1) ES2225161T3 (https=)
HK (1) HK1040057B (https=)
HU (1) HU229089B1 (https=)
ID (1) ID29468A (https=)
IL (2) IL141455A0 (https=)
MX (1) MXPA01000601A (https=)
NO (1) NO330353B1 (https=)
NZ (1) NZ510290A (https=)
OA (1) OA11601A (https=)
PL (1) PL200141B1 (https=)
PT (1) PT1107777E (https=)
RU (1) RU2251411C2 (https=)
TR (1) TR200100609T1 (https=)
TW (1) TWI233805B (https=)
WO (1) WO2001002002A1 (https=)
ZA (1) ZA200101589B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ITMI20021040A1 (it) * 2002-05-16 2003-11-17 Novuspharma Spa Composizioni farmaceutiche iniettabili di un derivato antracenedionico ad attivita' antitumorale
ATE528003T1 (de) 2002-07-31 2011-10-15 Senju Pharma Co Wässrige, flüssigkeitszubereitungen und lichtstabilisierte wässrige flüssigkeitszubereitungen
US8877168B1 (en) 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
US7119061B2 (en) * 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) * 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
AU2003299561A1 (en) * 2002-11-18 2004-06-15 Vicuron Pharmaceuticals Inc. Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
US7612066B2 (en) 2004-03-04 2009-11-03 Eisai R&D Management Co., Ltd. Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
JP2007538046A (ja) * 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
WO2006053383A1 (en) * 2004-11-22 2006-05-26 Anadis Ltd Bioactive compositions
KR101307999B1 (ko) 2004-12-01 2013-09-12 니폰 조키 세야쿠 가부시키가이샤 건조물 및 그 제조방법
WO2007010995A1 (ja) * 2005-07-20 2007-01-25 Kyowa Medex Co., Ltd. 生体試料中のペプチドの安定化方法
CN1962852B (zh) * 2006-11-27 2011-11-09 西北农林科技大学 红景天多糖在制备抗冻剂中的新用途及其产品和制备方法
CN102614492B (zh) * 2011-01-31 2013-12-11 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的液体药用组合物
CN102614491B (zh) * 2011-01-31 2014-04-16 上海天伟生物制药有限公司 一种含有棘白菌素类抗真菌剂米卡芬净的药用组合物及其制备方法和用途
NZ702063A (en) * 2012-05-22 2016-11-25 Paion Uk Ltd Compositions comprising short-acting benzodiazepines
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
CN110279698B (zh) 2013-03-15 2022-10-28 默沙东有限责任公司 头孢特咯瓒抗生素组合物
CN103330933B (zh) * 2013-04-26 2015-08-05 江苏豪森药业股份有限公司 含有米卡芬净或其盐的药物组合物
CN103330932B (zh) * 2013-04-26 2015-12-23 江苏豪森药业股份有限公司 一种米卡芬净或其盐的药物组合物
ES2978920T3 (es) * 2013-06-05 2024-09-23 Univ British Columbia Compuestos antifibrogénicos, métodos y usos de los mismos
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
KR101611349B1 (ko) 2014-04-14 2016-04-12 신우철 안정성이 개선된 밀크씨슬 엑스의 제형
EP3150621A4 (en) * 2014-05-29 2017-12-27 Shanghai Techwell Biopharmaceutical Co., Ltd Composition of cyclic peptide compound, preparation method for same, and uses thereof
MY190283A (en) * 2014-12-05 2022-04-12 Meiji Seika Pharma Co Ltd Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
ES2777942T3 (es) * 2014-12-31 2022-04-22 Galenicum Health S L U Composiciones farmacéuticas estables que comprenden micafungina
PL3058958T3 (pl) 2015-02-23 2019-02-28 Selectchemie Ag Kompozycja anidulafunginy
WO2018112330A1 (en) 2016-12-16 2018-06-21 Baxter International Inc. Micafungin compositions
US11185527B2 (en) 2017-06-26 2021-11-30 Wayne State University Methods and compositions relating to steroid hormone receptor-dependent cancers
RU2666148C1 (ru) * 2017-10-05 2018-09-06 Общество с ограниченной ответственностью "Новые Антибиотики" Способ получения водорастворимой лиофилизированной формы соли бис(2-тио-4,6-диоксо-1,2,3,4,5,6-гексагидропиримидин-5-ил)-(4-нитрофенил)метана
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
JPH03240727A (ja) 1990-02-15 1991-10-28 Toyo Jozo Co Ltd ニューモシスチス・カリニ肺炎治療剤
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
JP3193735B2 (ja) 1991-07-24 2001-07-30 株式会社リコー カラー画像形成装置の搬送装置
RU2095081C1 (ru) * 1991-12-13 1997-11-10 Акционерное общество "Биофа" Фармацевтическая композиция антивирусного действия
JPH0651641A (ja) 1992-07-30 1994-02-25 Olympus Optical Co Ltd 湿式現像装置
JPH06172204A (ja) * 1992-12-09 1994-06-21 Asahi Chem Ind Co Ltd アクレアシン類含有リポソーム製剤およびその製造法
JP3240727B2 (ja) 1993-02-25 2001-12-25 ソニー株式会社 偏平型陰極線管の画像歪補正装置
US6268338B1 (en) * 1993-04-30 2001-07-31 Merck & Co., Inc. Cyclohexapeptidyl amine compounds
IL109615A (en) * 1993-05-17 2000-12-06 Fujisawa Pharmaceutical Co Cyclic polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
RU2165423C2 (ru) * 1994-10-07 2001-04-20 Фудзисава Фармасьютикал Ко., Лтд. Полипептидное соединение, способ его получения и фармацевтическая композиция
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US6245349B1 (en) * 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
JP3123078B2 (ja) * 1996-03-08 2001-01-09 藤沢薬品工業株式会社 環状リポペプチド物質の脱アシル化法
PE63998A1 (es) * 1996-04-19 1998-10-30 Merck & Co Inc Composiciones anti-fungosas
JPH09301997A (ja) 1996-05-17 1997-11-25 Yamanouchi Pharmaceut Co Ltd 新規環状ペプチド系化合物
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
FR2755857B1 (fr) * 1996-11-19 1998-12-24 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees, a base de quinupristine et de dalfopristine et leur preparation
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
JPH10279498A (ja) * 1997-04-07 1998-10-20 Nippon Shinyaku Co Ltd 慢性関節リウマチ治療剤
JP3544847B2 (ja) * 1998-01-16 2004-07-21 三菱電機株式会社 光学的情報再生方法および装置
HK1040062A1 (zh) * 1999-03-03 2002-05-24 Eli Lilly And Company 含有成胶束表面活性剂的棘白菌素药物配方
HK1040369A1 (zh) * 1999-03-03 2002-06-07 Eli Lilly And Company 制备药物口服ecb配方和组合物的方法
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent

Also Published As

Publication number Publication date
CN100352495C (zh) 2007-12-05
CZ295720B6 (cs) 2005-10-12
EP1107777B1 (en) 2004-10-27
BRPI0006823B1 (pt) 2020-01-07
TWI233805B (en) 2005-06-11
NO330353B1 (no) 2011-04-04
HK1080724A1 (zh) 2006-05-04
RU2251411C2 (ru) 2005-05-10
ES2225161T3 (es) 2005-03-16
CN1315865A (zh) 2001-10-03
JP2003503462A (ja) 2003-01-28
CA2341568C (en) 2011-10-25
HK1040057B (zh) 2005-08-05
IL141455A0 (en) 2002-03-10
HK1040057A1 (en) 2002-05-24
DE60015279D1 (de) 2004-12-02
CN1636591A (zh) 2005-07-13
WO2001002002A1 (en) 2001-01-11
PL346297A1 (en) 2002-01-28
ZA200101589B (en) 2002-09-02
AU5572200A (en) 2001-01-22
ID29468A (id) 2001-08-30
NO20010893L (no) 2001-04-24
OA11601A (en) 2004-07-30
IL141455A (en) 2006-12-31
ATE280583T1 (de) 2004-11-15
CN1179748C (zh) 2004-12-15
NZ510290A (en) 2003-07-25
US7112565B2 (en) 2006-09-26
PT1107777E (pt) 2005-01-31
DE60015279T2 (de) 2005-05-25
BRPI0006823B8 (pt) 2021-05-25
KR100454784B1 (ko) 2004-11-05
HU229089B1 (en) 2013-07-29
PL200141B1 (pl) 2008-12-31
EP1107777A1 (en) 2001-06-20
AU752265B2 (en) 2002-09-12
JP4691866B2 (ja) 2011-06-01
AR024634A1 (es) 2002-10-16
HUP0103740A2 (hu) 2002-02-28
JP3381722B2 (ja) 2003-03-04
JP2002363097A (ja) 2002-12-18
CA2341568A1 (en) 2001-01-11
CZ20011186A3 (cs) 2001-09-12
TR200100609T1 (tr) 2001-07-23
US20040157769A1 (en) 2004-08-12
US6774104B1 (en) 2004-08-10
NO20010893D0 (no) 2001-02-22
KR20010072903A (ko) 2001-07-31
HUP0103740A3 (en) 2002-08-28
MXPA01000601A (es) 2002-04-08

Similar Documents

Publication Publication Date Title
BR0006823A (pt) Composição farmacêutica estabilizada, uso de composto de polipeptìdeo cìclico, preparação de injeção e pacote comercial
BRPI0111639B8 (pt) uso de uma molécula de ácido oligodeoxinucléico imunoestimulatório e composição farmacêutica.
BRPI9908319A (pt) composto amino cíclico, composição farmacêutica, medicamento contendo um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo, e, uso de um composto amino cíclico ou um sal farmacologicamente aceitável do mesmo.
DK0889876T3 (da) Meta-substituerede phenylensulfonamidderivater
BR0213877A (pt) Compostos orgânicos
IL123164A (en) Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
BR9814832A (pt) Composto, e, herbicida
BR9806413A (pt) Composto e uso do mesmo
KR870700620A (ko) 신규 약리학적 화합물
BR0010520A (pt) Novos compostos farmaceuticamente ativos
FR2677984B1 (fr) Derives d'imidazoline n-substitues, leur preparation, les compositions pharmaceutiques en contenant.
BR0108677A (pt) Novos compostos
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
BR9909781A (pt) Composto de formula (i), processo para sua preparação, composição farmacêutica compreendendo dito composto, seu uso e método.
DE69932424D1 (de) Melanocortin 1 rezeptorselektive verbindungen
NO20021859L (no) Nye oligosakkarider, deres fremstilling samt farmasöytiske preparater inneholdende oligosakkaridene
IT1229528B (it) Sali cefalosporinici e relative composizioni iniettabili, nonche' procedimento di preparazione
BR0209452A (pt) Composto de cefem, processo para sua preparação, composição farmacêutica e uso do composto
BR9712140A (pt) Agentes e processos para inibir a produção de citoquina, a adesão de cédulas e a produção de tnf - alfa e uso de um composto.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
NO983691L (no) Forbindelser tilh°rende amidiniumfamilien, farmas°ytiske preparater inneholdende disse samt anvendelse derav
KR880011112A (ko) 벤즈아제핀 설폰아미드 화합물
WO1999033825A8 (en) N-phenylamide and n-pyridylamide derivatives, method of preparing them and pharmaceutical compositons containing them
DK0447116T3 (da) Urinstof-derivater, deres fremstilling samt lægemidler indeholdende sådanne derivater
BR9807506A (pt) Derivados de amida e composições medicinais dos mesmos

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP)

Free format text: TRANSFERIDO POR FUSAO DE: FUJISAWA PHARMACEUTICAL CO., LTD.

B25D Requested change of name of applicant approved

Owner name: ASTELLAS PHARMA INC. (JP)

Free format text: ALTERADO DE: YAMANOUCHI PHARMACEUTICAL CO., LTD.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.20 NA RPI NO 2494 DE 23/10/2018 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/01/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/06/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/06/2020